YM 26734

inhibits group II phospholipase A2; structure given in first source

Also Known As:

4-(3,5-didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; YM-26734; 1-Dodecanone, 1,1'-(5-(3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl)-2,4,6-trihydroxy-1,3-phenylene)bis-

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Chromans: 3
        YM 26734: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Chromans: 3
        YM 26734: 1
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        YM 26734: 1

Experts

1.	Hamaguchi, Katsuhiko: 1 article (11/2003)
2.	Kudo, Ichiro: 1 article (11/2003)
3.	Kuwata, Hiroshi: 1 article (11/2003)
4.	Masuda, Seiko: 1 article (11/2003)
5.	Murakami, Makoto: 1 article (11/2003)
6.	Oh-ishi, Sachiko: 1 article (11/2003)
7.	Shimbara, Satoko: 1 article (11/2003)
8.	Yoshihara, Kumiko: 1 article (11/2003)

Related Diseases

1.	Pleurisy (Pleuritis) 11/30/2003 - "In contrast, sPLA(2)-IIA was dominant in carageenin-induced pleurisy in rats, where the accumulation of exudate fluids and leukocytes was significantly ameliorated by YM-26734. "
2.	Edema (Dropsy) 11/30/2003 - "12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear edema, in which the expression of sPLA(2)-IID, -IIF and -V was increased, was significantly reduced by YM-26734, a competitive sPLA(2)-IIA inhibitor that turned out to inhibit sPLA(2)-IID, -IIE, -V and -X as well. "